Big Pharma Needs New Drugs. China Has Them
Summary
Bloomberg’s Big Take Asia explores how China has become a global hub for biotech innovation, with Chinese firms now accounting for a third of the global drug pipeline. The episode highlights major licensing deals, such as Merck’s acquisition of the cancer drug sac-TMT, driven by China’s speed and cost advantages in clinical trials. While these partnerships offer US pharma a solution to patent cliffs, they raise concerns about eroding American dominance and geopolitical risks. The discussion covers the 2015 regulatory reforms that fueled this shift and the ongoing debate in Washington over w…
Topics discussed
Sponsorships: ChatGPT Work and Optum Healthcare
Sponsorship: Asana AI for human-agent teams
Intro: ASCO conference and Merck's new drug
Sacituzumab: Merck's licensed cancer treatment
China's rise in global biopharma pipeline
Show intro: Big Take Asia and episode overview
Chinese breakthroughs at ASCO 2024
China's shift from generics to innovation
2015 regulatory reforms and government support
The patent cliff and need for new drugs
How licensing deals work in pharma
Surge in US-China licensing deals
Speed and cost advantages of Chinese trials
Question: Is US dominance being undermined?
Sponsorship: ChatGPT Work
Sponsorship: Mastercard Small Business
Sponsorship: Wise international transfers
Record licensing deals and US market access
Validation and prestige for Chinese biotechs
Concerns about erosion of US biotech dominance
Geopolitical risks and supply chain dependency
US legislative response and policy debates
Future projections and the ethics of origin
Conclusion: Patient needs vs. political sensitivity
Outro and subscription call to action
Sponsorship: Cincinnati Insurance
Sponsorships: ChatGPT Work and Genius by Global
Listen ad-free on Castria